Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

With the West Bengal Assembly bypolls around the corner, a recent analysis by the West Bengal Election Watch and Association for Democratic Reforms (ADR) has shed light on the profiles of candidates in the fray. The study reveals that among the 41 candidates contesting in the upcoming bypolls, seven have serious criminal cases pending, while another seven are crorepatis. <h2>Criminal cases: BJP tops the list</h2>The ADR analysis shows that out of the seven candidates with serious criminal cases, four are from the Bharatiya Janata Party (BJP), two from the Trinamool Congress (TMC), and one from Congress. These cases range from non-bailable offences to electoral violations and financial fraud, with maximum punishments extending to five years or more. Offences in this category include serious crimes such as murder, kidnapping, and violations of the Prevention of Corruption Act or crimes against women. The bypolls will take place on November 13 in the constituencies of Coochbehar Sitai (SC), Haroa, Naihati, Medinipur, Taldangra, and Madarihat (ST). However, the affidavit for one candidate, independent contestant Pankaj Lohra from Madarihat (ST), could not be reviewed due to missing documents. <h2>Wealthiest candidates</h2>In addition to those with criminal cases, seven candidates declared assets exceeding Rs 1 crore. Congress leads in this regard, with three crorepati candidates, followed by the BJP with two, and the TMC and CPIM(L) with one each. According to the affidavits, the wealthiest candidate is TMC's <keyword id="23849799" type="General" weightage="20" keywordseo="sanat-dey" source="keywords">Sanat Dey</keyword> from Naihati, who has assets worth Rs 4.9 crore, including Rs 1.8 crore in immovable property. Following him is BJP's Ananya Roy Chakraborty, who is contesting from Taldangra, with assets totalling nearly Rs 3 crore. TMC’s Shyamal Kumar Ghosh, running for the Medinipur seat, declared assets of approximately Rs 1.69 crore. On average, the candidates’ assets are valued at around Rs 58.14 lakh. In contrast to the wealthiest candidates, Kashikanta Barman from the Kamatapur Peoples Party (United), contesting from Coochbehar Sitai (SC), has declared the lowest assets, amounting to just Rs 5,000. This wide range of wealth highlights the diverse financial backgrounds of candidates in the bypolls. (With inputs from agencies)

West Bengal bypolls to feature seven candidates with serious criminal cases including murder and kidnapping

In response to requests from multiple political parties, the <keyword id="19895782" type="General" weightage="20" keywordseo="election-commission" source="keywords">Election Commission</keyword> (EC) has decided to postpone upcoming by-elections in <keyword id="19894922" type="General" weightage="20" keywordseo="uttar-pradesh" source="keywords">Uttar Pradesh</keyword>, Kerala, and Punjab. Originally scheduled for November 13, the polls will now take place on November 20. This rescheduling aims to accommodate local festivities and boost voter turnout. The EC’s decision follows appeals from parties like the <keyword id="19895371" type="General" weightage="20" keywordseo="congress" source="keywords">Congress</keyword> (INC), Bharatiya Janata Party (BJP), Bahujan Samaj Party (BSP), and <keyword id="19984283" type="General" weightage="20" keywordseo="rashtriya-lok-dal" source="keywords">Rashtriya Lok Dal</keyword> (RLD), which expressed concerns over potential low turnout due to regional celebrations during the original polling date. The Congress highlighted that in Kerala's 56-Palakkad Assembly Constituency, many residents will participate in the Kalpathi Ratholsavam festival, a major event set to run from November 13 to 15. Similarly, representatives from the BJP, BSP, and RLD raised concerns in Uttar Pradesh, where people begin travelling several days in advance for <keyword id="22124352" type="General" weightage="20" keywordseo="kartik-purnima" source="keywords">Kartik Purnima</keyword>, an important festival observed in the state. In Punjab, the Congress pointed out that celebrations for the 555th Prakash Parv of Sri Guru Nanak Dev Ji are scheduled for November 15, with religious observances starting on November 13. These festivals are expected to draw significant portions of the electorate, particularly in rural areas. The EC has previously demonstrated flexibility to prioritise voter participation by adjusting poll dates to avoid clashes with religious or cultural events. In recent years, polling dates were modified for various elections, including the <keyword id="23790298" type="General" weightage="20" keywordseo="punjab-state-elections" source="keywords">Punjab State Elections</keyword> 2022 during the Shri Guru Ravidas Jayanti, and the <keyword id="23790297" type="General" weightage="20" keywordseo="uttar-pradesh-assembly-elections" source="keywords">Uttar Pradesh Assembly Elections</keyword> 2012 for <keyword id="23790296" type="General" weightage="20" keywordseo="barawafat" source="keywords">Barawafat</keyword>. Similar changes were made in Manipur, Mizoram, and Rajasthan to respect community schedules and increase voter convenience. With this adjustment, one assembly constituency in Kerala, four in Punjab, and nine in Uttar Pradesh will now hold their by-polls on November 20, while the dates for vote counting and final poll completion remain set for November 23 and 25, respectively. (With inputs from agencies)

By-polls in Uttar Pradesh, Kerala, and Punjab rescheduled due to clash with religious festivals — check new dates here

The <keyword id="1571" type="ORGANIZATION" weightage="20" keywordseo="Congress-party">Congress Party</keyword> has announced candidates for five Uttar Pradesh Assembly seats where by-elections are to be held on November 3. It will field Dr Kamlesh Singh from the Naugawan Sadat assembly seat and Sushil Chaudhary from the the Bulandshahr seat. The party has named Snehlata for the Tundla seat and Kripa Shankar for the Ghatampur seat. In Deoria, the Congress has fielded Mukund Bhaskar Mani Tripathi. Party sources said that the remaining two candidates for Bangarmau and Malhani will be announced later. SEE ALSO: <a href="https://www.businessinsider.in/policy/economy/news/rbis-mpc-keeps-the-policy-rates-unchanged-to-maintain-accommodative-stance-for-inflation/articleshow/78566955.cms">RBI says it has decided to 'look through' the current 'high inflation' as it won’t last long⁠ but leaves interest rates unchanged</a> <a href="https://www.businessinsider.in/business/corporates/news/tcs-beats-accenture-to-become-the-worlds-most-valuable-it-services-company/articleshow/78566487.cms">TCS beats Accenture to become the world’s most valuable IT services company — but this not the first time it has raced ahead</a> <a href="https://www.businessinsider.in/india/news/union-minister-ram-vilas-paswan-dies-at-74/articleshow/78558640.cms">India's consumer affairs minister Ram Vilas Paswan passes way at 74</a> <a href="https://www.businessinsider.in/science/space/news/mars-will-appear-bigger-redder-and-brighter-on-october-13-and-wont-get-this-close-to-earth-again-until-2035/articleshow/78556539.cms">Mars will appear bigger, redder, and brighter on October 13 — and won’t get this close to Earth again until 2035</a>

Congress names five candidates for UP bypolls — two more to be announced later

<ul><li>Covishield, Oxford’s coronavirus vaccine candidate being tested by Serum Institute of India in the country, could be ready as early as December. </li><li>Dr Reddy’s Laboratories on October 28 said that phase 3 trials of Russia’s <keyword id="8904563" type="UNKNOWN" weightage="20" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword>, Sputnik V, is likely to be finished by the end of March next year. </li><li>PM Modi has <a href="https://www.indiatoday.in/india/story/pm-narendra-modi-on-coronavirus-vaccine-distribution-1736090-2020-10-29">assured </a>that every Indian citizen will be vaccinated and no one will be left behind once a vaccine is available. </li></ul>Scientists are still looking for a cure for the deadly coronavirus, which has infected millions of people around the world. Two of the front runners in the race of vaccine — Moderna and Pfizer — are expected to launch their COVID-19 antidote by December. Whereas, Oxford-AstraZeneca’s vaccine is triggering an immune response for both young people and adults. The overall number of global coronavirus cases is nearing the 44 million mark, while the deaths have increased to more than 1,173,270,, according to Johns Hopkins University. There are over 100 potential vaccine candidates being tested on volunteers globally. In India, three vaccines are in advance trials. In India, 3 vaccines are under advanced stage trials while 4 others are in preclinical stages. PM Modi has <a href="https://www.indiatoday.in/india/story/pm-narendra-modi-on-coronavirus-vaccine-distribution-1736090-2020-10-29">assured </a>that every Indian citizen will be vaccinated and no one will be left behind once a vaccine is available. Oxford’s COVID-19 vaccine to be ready by December, SII to seek emergency licence Covishield, Oxford’s coronavirus vaccine candidate being tested by Serum Institute of India in the country, could be ready as early as December. "If we don't go for an emergency license, our trials should be over by December and then we can maybe launch in India in January subject to the UK trial, which is on the verge of being completed," <a href="https://www.ndtv.com/india-news/adar-poonawalla-coronavirus-vaccine-batch-1-likely-by-middle-of-next-year-2316971">Adar Poonawalla told NDTV in an interview.</a> However, Poonawalla believes data from UK clinical trials is going to play a key role in determining the further status. Dr Reddy’s says Phase 3 trials of Sputnik V will be over by March Dr Reddy’s Laboratories, on October 28, said that phase three trials of Russia’s COVID-19 vaccine, Sputnik V, is likely to be finished by the end of March next year. "Phase-3, we should finish somewhere by March, and then of course, it depends on the ability to compile the data, obtain the approvals, etc. It can be as early as the end of March or April /May and beyond. It depends on the results. It's a combination of phase-2, global phase-3 and phase-3 in India,"<a href="https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-hopes-to-finish-phase-3-trials-of-covid-19-vaccine-by-march-may/articleshow/78917320.cms"> Dr Reddy’s CEO Erez Israeli said.</a> Dr Reddy’s will test the vaccine on 100 volunteers for phase 2 trials, and is likely to recruit 1,400 volunteers in the phase 3 trials. Bharat Biotech is looking to raise manufacturing capacity above 500 million doses Bharat Biotech — one of three companies conducting advanced stage trials in India for its COVID-19 vaccine candidate — says it is producing Covaxin at its own risk. <a href="https://indianexpress.com/article/business/economy/trying-to-raise-manufacturing-capacity-above-500-million-doses-as-soon-as-possible-bharat-biotech-executive-director-6883341/">According to Bharat Biotech executive director Sai Prasad</a>, the pharma company has a manufacturing capacity of 150 million doses per year. However, it is looking to increase “capacity north of 500 million doses as soon as possible.” Bharat Biotech is looking at developing a new facility in Hyderabad — adjacent to the existing one. Biological E to begin phase I and phase II human trials of its <keyword id="9171681" type="UNKNOWN" weightage="20" keywordseo="Covid-19-vaccine-in-India">COVID-19 vaccine in India</keyword> Hyderabad-based Biological E <a href="https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biological-e-gets-nod-for-human-trials-of-covid-19-vaccine/articleshow/78919542.cms?from=mdr">got </a>the approval to conduct phase I and phase II human trials of its COVID-19 vaccine in India. The pharma company has partnered with an unidentified firm to conduct the trials, according to ET. Third phase human trial of COVID-19 vaccine to commence in Bhubaneswar soon The third phase of the human trial of the indigenous vaccine against COVID-19, COVAXIN, will commence at a private hospital in Bhubaneswar soon. Like the previous phases, half of the volunteers would receive placebo and the remaining half would be administered COVAXIN in this phase. Even health care workers would be recruited for the trial. The volunteers would be followed up over a considerable period of time to look at the efficacy of the vaccine in preventing the development of the Corona disease, according to Dr. E Venkata Rao, Principal Investigator in the COVAXIN human trial Bharat Biotech is looking to raise manufacturing capacity above 500 million doses Bharat Biotech — one of three companies conducting advanced stage trials in India for its COVID-19 vaccine candidate — says it is producing Covaxin at its own risk. <a href="https://indianexpress.com/article/business/economy/trying-to-raise-manufacturing-capacity-above-500-million-doses-as-soon-as-possible-bharat-biotech-executive-director-6883341/">According to Bharat Biotech executive director Sai Prasad</a>, the pharma company has a manufacturing capacity of 150 million doses per year. However, it is looking to increase “capacity north of 500 million doses as soon as possible.” Bharat Biotech is looking at developing a new facility in Hyderabad — adjacent to the existing one. SII finishes phase II trials of Oxford’s COVID-19 vaccine candidate in Mumbai Serum Institute of India (SII) and the Brihanmumbai Municipal Corporation have completed phase II trials of Oxford-AstraZeneca's COVID-19 vaccine candidate in Mumbai. The civic body is soon going to begin the third phase. “With the approval, we will be able to start the third phase of the trial once the first set of volunteers complete 28 days of the first vaccination. As per ICMR (Indian Council of Medical Research), the third trial can only be conducted on volunteers after a gap of 28 days,” said Suresh Kakani, additional commissioner, BMC. Every Indian citizen to get free COVID-19 vaccine, claims Union Minister Pratap Sarangi Union Minister Pratap Sarangi, on October 26, said that all people of the country would be given a free COVID vaccine. This comes amidst the demand by opposition parties to BJP to not use the vaccine as a<a href="https://www.businessinsider.in/india/news/bihar-election-manifesto-bharatiya-janata-party-bjp-promises-free-covid-vaccine-for-everyone/articleshow/78803796.cms"> poll promise </a>to win Bihar elections. The BJP announcement of free COVID vaccine for Bihar, where assembly polls begin this week, had kicked up a controversy with the opposition parties tearing into the NDA government, alleging that the ruling party was using the pandemic for political reasons. Union Finance Minister Nirmala Sitharaman had said the announcement was in order as it was an election manifesto announcement. Prime Minister Narendra Modi has announced that all people will be provided free of cost vaccines. An estimated ₹500 will be spent on vaccination of each person, Sarangi told reporters after addressing a campaign meeting for the November 3 assembly by-poll in Balasore. Intranasal vaccine will be easier to deliver, says Biotech founder Kiran Mazumdar Shaw In India, the intranasal vaccine will be easier to deliver than intramuscular injection, said Biocon’s Kiran Mazumdar Shaw. "Indeed intranasal vaccines will be far easier to deliver than intramuscular injections n Asha workers can be trained to deliver it at mass scale unlike IM injections which will need nurses, doctors n MBBS students which is a challenge," Biocon Executive Chairperson Kiran Mazumdar-Shaw tweeted Bharat Biotech gets nod to conduct phase 3 trial of its COVID-19 vaccine candidate Bharat Biotech, on October 22, got the approval from the Drug Controller General of India to conduct phase III trials of its COVID-19 vaccine in the country. "The firm has presented their data from Phase I and II along with animal challenge data in two species including NHP on the Inactivated Corona Virus Vaccine (BBV152) along with the proposal to conduct event-driven Phase III clinical trial to assess the efficacy of the vaccine," the expert panel of Subject Expert Committee (SEC) said. Indian government reportedly set aside $7 billion to vaccinate 1.3 billion people The Narendra Modi government has <a href="http://bloombergquint.com/coronavirus-outbreak/india-is-said-to-keep-7-billion-ready-for-vaccine-at-2-a-shot">reportedly </a>set aside ₹50,000 crore ($7 billion) to vaccinate 1.3 billion Indians against COVID-19, said Bloomberg citing sources. The government is estimating the overall cost of nearly $6-7 per person. Moreover, according to the government’s estimates <a href="https://timesofindia.indiatimes.com/india/india-sets-aside-7-billion-to-vaccinate-its-population-sources/articleshow/78808899.cms">a shot of a vaccine is likely to cost around $2. </a> IIT-Indore’s COVID-19 vaccine enters animal trial phase IIT-Indore’s potential COVID-19 vaccine has <a href="https://timesofindia.indiatimes.com/city/indore/iit-indores-covid-vaccine-in-animal-trial-phase/articleshow/78759625.cms">entered </a>the animal trials stage at the National Centre for Cell Science in Pune. “The research team, led by Dr Debasis Nayak, has received funds for development of a vaccine against SARS-CoV2. Nayak is a veterinarian and he is running trials on animals to study the vaccine’s side effects,” Prof Neelesh Kumar Jain said. Indian pharma Mankind partners with RDIF to market Sputnik V in India Russian Direct Investment Fund (RDIF) has inked a pact with Delhi-based Mankind Pharma to market and distribute Russia’s COVID-19 vaccine Sputnik V in India, <a href="https://www.livemint.com/news/india/rdif-inks-pact-with-mankind-pharma-for-marketing-sputnik-v-vaccine-11603005186344.html">according to Live Mint. </a> “It depends on how many doses they will give Mankind. RDIF has pacts with Russian and Korean manufacturers for around 50 million doses so far. Talks with Indian manufacturers are also ongoing. Mankind will get the doses once the approvals are in place and the doses are supplied," Mint reported citing sources. The pact comes after Dr Reddy’s Lab got the approval to conduct human trials of Sputnik V in India. Oxford-AstraZeneca’s COVID-19 vaccine will be ready by December The Serum Institute of India says Oxford-AstraZeneca’s potential COVID-19 vaccine will be ready by <a href="https://www.hindustantimes.com/india-news/vaccine-ready-by-december-in-market-by-march-serum-institute-reveals-covid-19-vaccine-planning/story-KWBryK3euM7dbWa06GYZfJ.html">December </a>and available in market by March 2021 after procuring a license. "India may get COVID-19 vaccine by March 2021 provided the regulators speed up the process as multiple manufacturers are working on it," Jadhav said at the India Vaccine Accessibility e-summit organised by HEAL Foundation in association with ICCIDD. Meanwhile, Serum Institute has proposed the Drug Controller General of India to broaden the norms of clinical trials by including people with different conditions from all ages. Bharat Biotech partners with Washington University for an intranasal vaccine Union Health Minister Harsh Vardhan, on October 19, informed that Bharat Biotech would <a href="https://www.ndtv.com/india-news/serum-institute-bharat-biotech-to-start-intranasal-covid-19-vaccine-trials-soon-health-minister-2312103">develop </a>an intranasal vaccine for Sars-CoV-2. According to Harsh Vardhan, Bharat Biotech has entered into an agreement with Washington University and St. Louis University for the trials of the nasal vaccine candidate. "It (Bharat Biotech) has entered into an agreement with Washington University's School of Medicine under which the company will conduct trials, produce and market an intranasal vaccine for the COVID-19," Vardhan told his social media audience at his weekly webinar, Sunday Samvaad. The Phase 1 trials of the vaccine candidate will take place in St Louis University's vaccine and treatment evaluation unit, while further stages of the trials will be conducted in India. Dr Reddy’s receive approval for Sputnik V’s human trial in India Dr.Reddy’s Laboratories and Russian Direct Investment Fund, Russia’s sovereign wealth fund, on October 17, announced that they have received approval from the Drug Control General of India to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India. Dr Reddy’s said that this will be a multi-center and randomised controlled study, which will include safety and immunogenicity study. Additionally, Phase 3 clinical trial of the vaccine commenced in the UAE last week On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform. A month later, Dr Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. Sputnik V is currently undergoing Phase 3 clinical trials in Russia and the proposed number of subjects is 40,000. Apollo Hospitals is ready to administer 1 million COVID-19 vaccines daily Apollo Hospitals announced on October 15 that it is prepared to administer one million Covid-19 vaccines per day whenever the vaccine is rolled out. The group said it will leverage its robust pan-India network of 19 medicine supply hubs with cold chain facilities, 70 hospitals, over 400 clinics, 500 corporate health centres and 4000 pharmacies alongside their omni-channel digital platform to ensure massive administration capacity of COVID-19 vaccines. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/policy/economy/news/another-round-of-economic-stimulus-not-off-the-table-according-to-sitharaman/articleshow/78760271.cms">Another round of economic stimulus not off the table, according to Sitharaman</a>

You Searched For "bypolls November 13" and got 4 results

West Bengal bypolls to feature seven candidates with serious criminal cases including murder and kidnapping

BI India Bureau

By-polls in Uttar Pradesh, Kerala, and Punjab rescheduled due to clash with religious festivals — check new dates here

BI India Bureau

Congress names five candidates for UP bypolls — two more to be announced later

IANS

COVID-19 vaccine updates in India: Oxford’s COVID-19 vaccine trials can be over by December, if SII doesn’t go for emergency licence

BI India Bureau

Popular Keywords

Buying Guides